序列ctDNA了解PARPi抗性

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-12-09 DOI:10.1038/s41585-024-00984-7

Annette Fenner

引用次数: 0

摘要

聚（adp -核糖）聚合酶抑制（PARPi）是一种治疗同源重组修复（HRR）基因缺陷的去势抵抗性前列腺癌（CRPC）的有效方法。然而，对PARPi的耐药性可能会产生，例如通过恢复BRCA功能的突变。HRR基因的逆转突变可导致PARPi耐药，但在纯合子突变患者中不会出现这种情况，这可能解释了为什么纯合子BRCA2突变患者对PARPi的反应更持久。纯合突变患者的耐药机制尚不清楚，这种突变如何发生也不清楚。《癌细胞》杂志的一项研究试图阐明这些机制，使用来自II期TOPARP-B试验的数据，该试验证明奥拉帕尼对具有双等位基因dna损伤修复突变的转移性CRPC患者具有抗肿瘤活性。值得注意的是，最持久的反应出现在BRCA2纯合缺失患者中。这些数据也得到了PROFound试验的支持，该试验显示，与纯合突变相比，BRCA2杂合突变患者的放射无进展生存期（rPFS）降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serial ctDNA to understand PARPi resistance

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.